posted on 2023-09-01, 14:20authored byShruti Lal, Neil E. Bhola, Bee-Chun Sun, Yuping Chen, Tom Huang, Vivian Morton, Kevin X. Chen, Shanghua Xia, Haoyu Zhang, Nehal S. Parikh, Qiuping Ye, O. Petter Veiby, David I. Bellovin, Yuhua Ji
ZL-2201 reduces DNA damage-induced MCM2 phosphorylation (Ser108).
Funding
ZaiLab (US) LLC
History
ARTICLE ABSTRACT
ZL-2201, a potent and selective DNA-PK inhibitor, can target tumor models in combination with DNA DSB-inducing agents such as radiation or doxorubicin, with potential to improve recurrent therapies in the clinic.